Show simple item record

dc.contributor.authorRossello, Xavier 
dc.contributor.authorPiñero, Antonio
dc.contributor.authorFernandez-Jimenez, Rodrigo 
dc.contributor.authorSanchez-Gonzalez, Javier 
dc.contributor.authorPizarro, Gonzalo 
dc.contributor.authorGalan-Arriola, Carlos 
dc.contributor.authorLobo-Gonzalez, Manuel 
dc.contributor.authorVilchez, Jean Paul 
dc.contributor.authorGarcia-Prieto, Jaime 
dc.contributor.authorGarcia-Ruiz, Jose M 
dc.contributor.authorGarcia-Alvarez, Ana 
dc.contributor.authorSanz-Rosa, David 
dc.contributor.authorIbanez, Borja 
dc.date.accessioned2020-04-13T08:58:03Z
dc.date.available2020-04-13T08:58:03Z
dc.date.issued2018-08
dc.identifier.citationJ Cardiovasc Transl Res. 2018; 11(4):310-318es_ES
dc.identifier.issn1937-5387es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9506
dc.description.abstractThe administration of the selective β3 adrenergic receptor (β3AR) agonist BRL-37344 protects from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits its translatability. We tested the cardioprotective effect of mirabegron, the first-in-class β3AR agonist approved for human use. A dose-response study was conducted in 6 pigs to select the highest intravenous dose of mirabegron without significant detrimental hemodynamic effect. Subsequently, closed chest anterior myocardial infarction (45 min ischemia followed by reperfusion) was performed in 26 pigs which randomly received either mirabegron (10 μg/kg) or placebo 5 min before reperfusion. Day-7 cardiac magnetic resonance (CMR) showed no differences in infarct size (35.0 ± 2.0% of left ventricle (LV) vs. 35.9 ± 2.4% in mirabegron and placebo respectively, p = 0.782) or LV ejection fraction (36.3 ± 1.1 vs. 34.6 ± 1.9%, p = 0.430). Consistent results were obtained on day-45 CMR. In conclusion, the intravenous administration of the clinically available selective β3AR agonist mirabegron does not reduce infarct size in a swine model of IRI.es_ES
dc.description.sponsorshipDr. Rossello has received support from SEC-CNIC CARDIOJOVEN Program. R. F-J is a recipient of funding from the European Union's Horizon 2020 research and innovation program under grant agreement No MSCA-IF-GF-707642. This study was partially supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) through the Carlos III Institute of Health-Fondo de Investigacion Sanitaria (PI10/02268, PI13/01979, and PI16/02110), and the Fondo Europeo de Desarrollo Regional (FEDER, RD: SAF2013-49663-EXP). This study forms part of a Master Research Agreement between the CNIC and Philips Healthcare. The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (MEIC award SEV-2015-0505).es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAcute myocardial infarctiones_ES
dc.subjectCardioprotectiones_ES
dc.subjectIschemia/reperfusion injuryes_ES
dc.subjectMirabegrones_ES
dc.subjectTranslational modelses_ES
dc.subjectβ3 adrenergic receptores_ES
dc.subject.meshAcetanilides es_ES
dc.subject.meshAdrenergic beta-3 Receptor Agonists es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshMagnetic Resonance Imaging, Cine es_ES
dc.subject.meshMale es_ES
dc.subject.meshMyocardial Infarction es_ES
dc.subject.meshMyocardial Reperfusion Injury es_ES
dc.subject.meshMyocardium es_ES
dc.subject.meshRandom Allocation es_ES
dc.subject.meshSwine es_ES
dc.subject.meshThiazoles es_ES
dc.subject.meshVentricular Function, Left es_ES
dc.subject.meshVentricular Remodeling es_ES
dc.titleMirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarctiones_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID30073540es_ES
dc.format.volume11es_ES
dc.format.number4es_ES
dc.format.page310-318es_ES
dc.identifier.doi10.1007/s12265-018-9819-8es_ES
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares (CNIC)es_ES
dc.contributor.funderSociedade Española de Cardiologíaes_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es_ES
dc.contributor.funderFundación ProCNICes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1937-5395es_ES
dc.relation.publisherversionhttps://doi.org/10.1007/s12265-018-9819-8es_ES
dc.identifier.journalJournal of cardiovascular translational researches_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/707642es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI10/02268es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/01979es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/02110es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2013-49663-EXPes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional